ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

被引：0
|
作者：
Harrington, Bonnie K. [1 ]
Gulrajani, Michael [2 ]
Covey, Todd [2 ]
Kaptein, Allard [3 ]
Van Lith, Bart [3 ]
Izumi, Raquel [2 ]
Hamdy, Ahmed [2 ]
Ulrich, Roger Glenn [2 ]
Byrd, John C. [4 ]
Lannutti, Brian J. [2 ]
Johnson, Amy J. [4 ]
机构：
[1] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA
[2] Acerta Pharma, Redwood City, CA USA
[3] Acerta Pharma, Oss, Netherlands
[4] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies
    Abdelhameed, Ali S.
    Alanazi, Amer M.
    Bakheit, Ahmed H.
    Hassan, Eman S.
    Herqash, Rashed N.
    Almutairi, Fahad M.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 127 : 536 - 543
  • [22] Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target
    Ponader, Sabine
    Balasubramanian, Sriram
    Pham, Lan V.
    Chen, Jun
    Tamayo, Archito T.
    Wang, Michael
    O'Brien, Susan
    Wierda, William G.
    Keating, Michael J.
    Ford, Richard J.
    Burger, Jan A.
    BLOOD, 2011, 118 (21) : 1576 - 1576
  • [23] BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
    Li, Na
    Sun, Zhijian
    Liu, Ye
    Guo, Mingming
    Zhang, Yilu
    Zhou, Dongping
    Zhang, Bo
    Su, Dan
    Zhang, Shuo
    Han, Jing
    Gao, Yajuan
    Guo, Yunhang
    Wang, Zhiwei
    Wei, Min
    Luo, Lusong
    Wang, Lai
    CANCER RESEARCH, 2015, 75
  • [24] Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor
    Xiao, Zhou-Peng
    Liao, Min
    Huang, Xue-Juan
    Wang, Yu-Tong
    Lan, Xiao-Cui
    Wang, Xue-Ying
    Li, Xi-Tao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [25] Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
    Zhu, Zhen
    Ling, Lanlan
    Qi, Lezhong
    Chong, Yue
    Xue, Li
    ONCOTARGETS AND THERAPY, 2020, 13 : 4113 - 4122
  • [26] A novel Bruton's tyrosine kinase (BTK) inhibitor with anticancer and anti-inflammatory activities
    Jain, M.
    Chatterjee, A.
    Mohapatra, J.
    Bandhyopadhyay, D.
    Ghoshdostidar, K.
    Bhatnagar, U.
    Patel, H.
    Bahekar, R.
    Ramanathan, V.
    Patel, P.
    Desai, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S63 - S63
  • [27] Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
    Turner, Timothy J.
    Brun, Pricilla
    Gruber, Ross C.
    Ofengeim, Dimitry
    DRUGS IN R&D, 2024, 24 (02) : 263 - 274
  • [28] Characterizing first- & second-generation follow on drugs: Clinical trial & development timelines of Bruton tyrosine kinase (BTK) inhibitors
    Varma, Ashwin
    Feldman, William B.
    Kesselheim, Aaron S.
    Cliff, Edward R.
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
    Jennifer R. Brown
    Current Hematologic Malignancy Reports, 2013, 8 : 1 - 6
  • [30] Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)
    Yu, Tianshu
    Wang, Lingjun
    Ni, Xiaofei
    Hou, Yu
    Liu, Xinguang
    Hou, Ming
    BLOOD, 2021, 138
12345